297 related articles for article (PubMed ID: 6260870)
1. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
Schaad UB; McCracken GH; Loock CA; Thomas ML
J Infect Dis; 1981 Feb; 143(2):156-63. PubMed ID: 6260870
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.
McCracken GH; Nelson JD; Grimm L
Antimicrob Agents Chemother; 1982 Feb; 21(2):262-7. PubMed ID: 6280599
[TBL] [Abstract][Full Text] [Related]
3. Activity of moxalactam and cefotaxime alone and in combination with ampicillin or penicillin against group B streptococci.
Landesman SH; Corrado ML; Cherubin CE; Sierra MF
Antimicrob Agents Chemother; 1981 May; 19(5):794-7. PubMed ID: 6271048
[TBL] [Abstract][Full Text] [Related]
4. Penetration of cefotaxime and moxalactam into cerebrospinal fluid of rabbits with experimentally induced Escherichia coli meningitis.
Nolan CM; Ulmer C
Rev Infect Dis; 1982; 4 Suppl():S396-400. PubMed ID: 6294789
[TBL] [Abstract][Full Text] [Related]
5. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
Hall WH; Opfer BJ; Gerding DN
Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
[TBL] [Abstract][Full Text] [Related]
6. Third-generation cephalosporins: a critical evaluation.
Barriere SL; Flaherty JF
Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
[TBL] [Abstract][Full Text] [Related]
7. Activity of cefotaxime and ceftriaxone alone and in combination with penicillin, ampicillin and piperacillin against neonatal meningitis pathogens.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1985 Sep; 16(3):327-34. PubMed ID: 3932295
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.
Schaad UB; McCracken GH; Loock CA; Thomas ML
Antimicrob Agents Chemother; 1980 Mar; 17(3):406-11. PubMed ID: 6448576
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.
Shelton S; Nelson JD; McCracken GH
Antimicrob Agents Chemother; 1980 Sep; 18(3):476-9. PubMed ID: 6252837
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.
Baker CN; Thornsberry C; Jones RN
Antimicrob Agents Chemother; 1980 Apr; 17(4):757-61. PubMed ID: 6249195
[TBL] [Abstract][Full Text] [Related]
11. Mecillinam alone and in combination with ampicillin or moxalactam in experimental Escherichia coli meningitis.
Schaad UB; Grimm LM; Beskid G; Cleeland R; Nelson JD; McCracken GH
Infection; 1982; 10(2):90-6. PubMed ID: 6284652
[TBL] [Abstract][Full Text] [Related]
12. Beta-lactam antibiotic susceptibility of bacteria responsible for neonatal meningitis.
Bradsher RW; Ulmer WC
Chemotherapy; 1983; 29(3):213-7. PubMed ID: 6409519
[TBL] [Abstract][Full Text] [Related]
13. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
Mouton RP; Bongaerts GP; van Gestel M; Bruggeman-Ogle KM
Chemotherapy; 1981; 27(5):318-24. PubMed ID: 6455258
[TBL] [Abstract][Full Text] [Related]
14. Potential value of cefoperazone in bacterial meningitis: experimental studies.
Durack DT; Perfect JR
Drugs; 1981; 22 Suppl 1():60-4. PubMed ID: 6269824
[TBL] [Abstract][Full Text] [Related]
15. Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.
Magnussen CR; Sammartino MT; Ernest KD
Antimicrob Agents Chemother; 1982 Jul; 22(1):154-6. PubMed ID: 6289736
[TBL] [Abstract][Full Text] [Related]
16. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
Fitzpatrick BJ; Standiford HC
Pharmacotherapy; 1982; 2(4):197-212. PubMed ID: 6221237
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of cefoperazone, moxalactam, cefotaxime, trimethoprim and sulphamethoxazole in experimental meningitis.
Perfect JR; Durack DT
J Antimicrob Chemother; 1981 Jul; 8(1):49-58. PubMed ID: 6265429
[No Abstract] [Full Text] [Related]
18. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
Standiford HC; Drusano GL; McNamee WB; Tatem B; Ryan PA; Schimpff SC
Rev Infect Dis; 1982; 4 Suppl():S585-94. PubMed ID: 6296967
[TBL] [Abstract][Full Text] [Related]
19. Differences among moxalactam, cefoperazone, and cefotaxime in activity against multiple-antibiotic-resistant gram-negative bacteria.
Preston DA
Rev Infect Dis; 1982; 4 Suppl():S516-21. PubMed ID: 6296965
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.
Schaad UB; McCracken GH; Threlkeld N; Thomas ML
J Pediatr; 1981 Jan; 98(1):129-36. PubMed ID: 6450277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
